Northwest Biotherapeutics, Inc. (NWBO)
|Net Income (ttm)||-242.65M|
|Trading Day||February 25|
|Day's Range||1.43 - 1.58|
|52-Week Range||0.141 - 2.51|
NWBO has run an 18-year long trial in GBM, one of the deadliest of cancers. It has been mired in controversies, and it has no cash.
In a short period of time, this immunotherapy biotech could either become a multi-bagger or trade near $0.
With Data Lock just announced, Top Line Date is imminent.
Northwest Biotherapeutics, a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. It is developing DCVax-L that is in Phase III clinical trials to treat Glioblastome multiforme, a brain cancer; and DCVax-Direct, which is in Phase I/II clinical trials to treat various inoperable solid tumor cancers. The company was foun... [Read more...]
|Stock Exchange |
|Ticker Symbol |
In 2019, NWBO's revenue was $2.41 million, an increase of 484.95% compared to the previous year's $412,000. Losses were -$20.30 million, -43.30% less than in 2018.